Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The present invention provides a compound represented by the following Formula (I):

##STR00001##

wherein ring A is a C5-C7 non-aromatic carbocycle or a 5- to 7-membered non-aromatic heterocycle; ring B is a benzene ring or the like; Q is —NHC(O)— or a 5-membered aromatic heterocycle; R.sup.1 is each independently halogen or the like; R.sup.2a and R.sup.2b are each independently hydrogen, alkyl, or haloalkyl; R.sup.3 is alkyl or the like; R.sup.4 and R.sup.5 are each independently hydrogen or the like; R.sup.6 is each independently halogen, alkyl, haloalkyl, alkyloxy, haloalkyloxy, or alkyloxyalkyl; n is an integer of 1 to 3; and m is an integer of 0 to 3.

The present invention provides a compound represented by the following Formula (I):

##STR00001##

wherein ring A is a C5-C7 non-aromatic carbocycle or a 5- to 7-membered non-aromatic heterocycle; ring B is a benzene ring or the like; Q is —NHC(O)— or a 5-membered aromatic heterocycle; R.sup.1 is each independently halogen or the like; R.sup.2a and R.sup.2b are each independently hydrogen, alkyl, or haloalkyl; R.sup.3 is alkyl or the like; R.sup.4 and R.sup.5 are each independently hydrogen or the like; R.sup.6 is each independently halogen, alkyl, haloalkyl, alkyloxy, haloalkyloxy, or alkyloxyalkyl; n is an integer of 1 to 3; and m is an integer of 0 to 3.

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L.sup.1-L.sup.2-L.sup.P-NH—(CH.sub.2)n.sup.1-L.sup.a-(CH.sub.2)n.sup.2-C(═O)— wherein the anti-HER2 antibody is connected to the terminal L.sup.1, and the antitumor compound is connected to the carbonyl group of the —(CH.sub.2)n.sup.2-C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position. ##STR00001##

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L.sup.1-L.sup.2-L.sup.P-NH—(CH.sub.2)n.sup.1-L.sup.a-(CH.sub.2)n.sup.2-C(═O)— wherein the anti-HER2 antibody is connected to the terminal L.sup.1, and the antitumor compound is connected to the carbonyl group of the —(CH.sub.2)n.sup.2-C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position. ##STR00001##

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer contains, as a first host material, a first compound represented by a formula (1) below and having a group represented by a formula (11) below, the second emitting layer contains a second compound represented by one of formulae (2-1D) to (2-4D) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer.

##STR00001## ##STR00002##

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer contains, as a first host material, a first compound represented by a formula (1) below and having a group represented by a formula (11) below, the second emitting layer contains a second compound represented by one of formulae (2-1D) to (2-4D) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer.

##STR00001## ##STR00002##

An organic compound having the structure of Formula (I), shown below, is disclosed. When used in a hole injection layer or a hole transporting layer, it can greatly improve the balance of electron holes and electron transporting of a device, thereby bringing excellent device effects, for example, improving the efficiency and lifetime of a device. At the same time, it also achieves a good effect when the organic compound having the structure of Formula (I) is used as a P-type conductive doping material in a charge generation layer of a multi-layer OLED device. ##STR00001##

An organic compound having the structure of Formula (I), shown below, is disclosed. When used in a hole injection layer or a hole transporting layer, it can greatly improve the balance of electron holes and electron transporting of a device, thereby bringing excellent device effects, for example, improving the efficiency and lifetime of a device. At the same time, it also achieves a good effect when the organic compound having the structure of Formula (I) is used as a P-type conductive doping material in a charge generation layer of a multi-layer OLED device. ##STR00001##